4/9
04:04 pm
crvs
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis [Yahoo! Finance]
High
Report
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis [Yahoo! Finance]
4/9
04:01 pm
crvs
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Medium
Report
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
4/1
12:17 pm
crvs
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
3/27
02:11 pm
crvs
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "neutral" rating re-affirmed by analysts at Mizuho. They now have a $3.50 price target on the stock.
Low
Report
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "neutral" rating re-affirmed by analysts at Mizuho. They now have a $3.50 price target on the stock.
3/21
10:01 am
crvs
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/20
08:08 am
crvs
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $8.00 to $7.00. They now have an "outperform" rating on the stock.
Low
Report
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $8.00 to $7.00. They now have an "outperform" rating on the stock.
3/19
04:19 pm
crvs
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
High
Report
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
3/19
04:02 pm
crvs
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Medium
Report
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
3/13
04:02 pm
crvs
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024
Medium
Report
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024
3/9
09:14 am
crvs
We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Needs To Drive Business Growth Carefully [Yahoo! Finance]
Medium
Report
We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Needs To Drive Business Growth Carefully [Yahoo! Finance]
2/12
11:10 am
crvs
Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up [Yahoo! Finance]
Low
Report
Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up [Yahoo! Finance]
2/12
08:43 am
crvs
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases [Yahoo! Finance]
Medium
Report
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases [Yahoo! Finance]
2/12
08:30 am
crvs
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases
Medium
Report
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases
2/8
04:24 pm
crvs
Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma [Yahoo! Finance]
Low
Report
Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma [Yahoo! Finance]
2/8
04:05 pm
crvs
Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma
Medium
Report
Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma
2/6
04:15 pm
crvs
Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer [Yahoo! Finance]
Low
Report
Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer [Yahoo! Finance]
2/6
04:05 pm
crvs
Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer
Low
Report
Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer